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Abstract
Timolol inhibits erythrocyte membrane acetylcholinesterase (AChE) enzyme activity originates less active enzyme complex forms unable to change the normal values 
of the nitric oxide (NO) efflux from erythrocytes. The active complex resulting from acetylcholine (ACh) binding to AChE induces higher values of NO efflux. 
Increased values of NO efflux were also observed in presence of high fibrinogen (Fib) concentration with return to normal levels of NO efflux when ACh is added. 
Association between NO efflux and erythrocyte deformability values has been evidenced. 
The objective of this study was to evaluate the effects of high fibrinogen concentration on the erythrocyte NO metabolism and deformability in presence of timolol 
without and plus adenylyl cyclase or plus guanylyl cyclase inhibitors.
Blood samples from healthy donors were divided in aliquots without (control) or with Fib or Fib plus timolol in absence or presence of adenylyl cyclase inhibitor 
(MDL) or guanylyl cyclase inhibitor (Ly). Erythrocyte deformability (ED), NO efflux, S-nitrosoglutathione (GSNO), nitrite and nitrate values were evaluated by 
referenced methods.
Fib increased the values of NO efflux under the influence of timolol or MDL. Increased values of NO efflux, GSNO, nitrites and nitrates where obtained in presence 
of Fib plus timolol plus MDL in relation to control to Fib or Fib plus MDL aliquots. Increased nitrites and nitrates values where obtained in presence of Fib plus 
timolol plus Ly in relation to control, to Fib and Fib plus Ly. Only at high shear stress increased ED values was observed in Fib plus timolol in absence and presence 
of MDL.
In conclusion fibrinogen plus timolol increased ED at high shear stress without or with MDL. Fibrinogen increased NO efflux from erythrocytes and GSNO, nitrite 
and nitrate levels in presence of timolol plus guanylyl cyclase inhibitor. 
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Introduction 
The plasma fibrinogen (Fib) molecule participates in fibrin 
formation, red blood cells (RBCs) aggregation and when at high 
concentrations is known as an inflammatory acute phase protein 
[1-3]. Fibrinogen binding to erythrocyte CD47 receptor protein 
belonging to Rh complex that stablish contact with 4.2 cytoskeletal 
protein which interact with band 3 protein [4,15]. Mimicking, in vitro 
hyperfibrinogenemia increased values of nitric oxide (NO) efflux from 
RBCs dependent on band 3 protein phosphorylation degree and lower 
cyclic adenosine monophosphate (cAMP) concentration was evidenced 
[6,7]. Maintaining high Fib concentrations, the levels of NO efflux 
from RBCs normalize by the presence of acetylcholine (ACh) binding 
to RBCs membrane acetylcholinesterase (AChE) [8]. The explanation 
comes from the signal transduction pathway initiate by the AChE-ACh 
active complex forms [9,10]. So, activation of protein kinase C (PKC) 
inhibits by phosphorylation the phosphodiesterase (PDE3) resulting 
increased amount of cAMP concentration that abolish the higher NO 
efflux induced by hyperfibrinogenemia observed in absence of ACh 
[8-10]. While ACh increase erythrocyte deformability (ED) at high 
shear stress, high Fib concentrations increase it at low shear stress 
under band 3 dephosphorylated by protein tyrosine kinase (PTK syk) 
inhibition [11,12]. 
Timolol is a moderate inhibitor of erythrocyte AChE and normal 
values of NO efflux from RBCs has been verified under AChE-timolol 
complex, which are lower than those evaluated when AChE-ACh 
active complex forms are presented in eryrthrocytes [13-16]. Increased 
NO efflux, S-nitrosoglutathione (GSNO), nitrite and nitrate values 
were evidenced in presence of timolol plus adenylyl cyclase inhibitor 
(MDL) [17]. It was observed an increase in ED at high shear stress 
induced by the simultaneous presence of timolol and band 3 protein 
dephosphorylation by PTK syk inhibitor [17].
The aim of this study was to evaluate the effects of high fibrinogen 
concentration on the erythrocyte NO metabolism and deformability in 
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from Sigma (St Louis, MO, USA). For protein tyrosine). The human 
fibrinogen was purchased from Sigma (Poole, UK). The chosen 
concentrations for fibrinogen were based on its physiological levels 
and on previous studies [18]. Timolol maleate was purchased from 
Laboratórios Químico- Farmacêuticos, Chibret, Lda. Nitrate reductase 
from Aspergillus Niger, NADPH (tetra sodium salt), sodium nitrate, 
sodium nitrite and atropine were all from Sigma Chemical Co., St 
Louis, MO, USA. The Griess Reagent kit was purchased from Molecular 
Probes, Eugene, USA. Sodium chloride was purchased from AnalaR 
(UK) and chloroform and ethanol 95% from MERCK, Darmstadt, 
Germany. Blood samples were collected into tubes BD Vacutainer TM 
with Lithium heparin (17UI/mL) as an anticoagulant. 
Blood sampling and experimental model 
This in vitro study was performed under the protocol established 
with the Portuguese Institute of Blood in Lisbon. All males donors 
(N=10; aged between 30 and 40 years old) were duly informed and 
signed their agreement. 
Blood samples were collected into tubes with lithium heparin (17 
IU/ml) as anticoagulant. Total blood was divided into eight aliquots 
of 1 ml each and centrifuged at 11 000 rpm (Biofuge 15 centrifuge, 
Heraeus) during 1minute at room temperature. Then 10 μL of plasma 
were replaced by the same volume of either physiological serum 
(control aliquot) or fibrinogen NaCL isotonic solutions pH 7,4 (30 
mg/dL) or timolol or Fib plus MDL or Fib plus Ly or Fib plus timolol 
or Fib plus MDL plus timolol or Fib plus Ly plus timolol plus each 
inhibitor, so that the final concentration of timolol and each inhibitor 
in the whole blood aliquots was 10−5 M. Besides other concentrations 
(5 × 10−5, 10−6 and 5 × 10−6 M) were tested, no significant alterations 
were observed with these concentrations in relation to 10−5 M. Then 
the blood sample was homogenized by gently inversion incubated for 
15 minutes at room temperature. At the end of incubation samples 
were centrifuged and plasma removed for fibrinogen concentration 
assessment. Then erythrocyte deformability, NO efflux from RBC and 
the other NO derivative molecules were determined following the 
methods described next.
Determination of fibrinogen concentration by clot-based 
technology
Plasma fibrinogen concentrations were evaluated using the 
Fibritimer BFT* //Analyser (Dade Behring, Marburg GmbH, Germany) 
based on the Clot technology.
Measurement of erythrocyte NO efflux, nitrite, nitrate, GSNO 
and peroxynitrite
Following incubation, blood samples were centrifuged and sodium 
chloride 0.9 % with a pH 7.0 was added to establish a hematocrit of 
0.05%. The suspension was mixed by gentle inversion.
In order to quantify amperometric NO quantification, we used the 
amino-IV sensor (Innovative Instruments Inc. FL, USA), according 
to the method described previously [19] NO diffuses through the 
gas-permeable membrane tripleCOAT of the sensor probe and it 
is then oxidized at the working platinum electrode, resulting on 
an electric current. The redox current is proportional to the NO 
concentration outside the membrane and was continuously monitored 
with a computerized inNOTM system, (with a software version 1.9, 
Innovative Instruments Inc., Tampa, FL, USA). Calibration of the 
NO sensor was performed daily. For each test, the NO sensor was 
immersed vertically in the erythrocyte suspension vials and allowed to 
stabilize for 30 min to achieve basal NO levels. 30 μl of acetylcholine 
was added to the erythrocyte suspension samples in order to achieve 
final concentrations of 10μM of ACh and NO. Data was recorded from 
the constantly stirred suspensions at room temperature. 
The measurement of nitrite/nitrate concentration was performed 
using the spectrophotometric Griess method as already described 
[20], after submitting the pellet of each centrifuged blood sample to 
haemolysis and haemoglobin precipitation. Haemolysis was induced 
with distilled water and hemoglobin precipitation with a mixture of 
ethanol and chloroform (5v/3v). The nitrite concentrations were 
measured with the spectrophotometric Griess reaction, at 548 nm. For 
nitrate measurement, this compound was first reduced to nitrites in 
presence of nitrate reductase [21].
S-nitrosoglutathione (GSNO) was measured utilizing colorimetric 
solutions containing a mixture of sulfanilic acid (B component 
of Griess reagent) and NEDD (A component of Griess reagent), 
consisting of 57.7 mM of sulfanilic acid and 1 mg/mL of NEDD were 
dissolved in phosphate-buffered solution (PBS; pH 7.4). To constitute 
the 10 mM HgCl2 (Aldrich) mercury ion stock solutions were prepared 
in 0.136g/50mL of dimethyl sulfoxide (DMSO) (Aldrich). GSNO was 
diluted to the following desired concentrations: 7,5 μM; 15 μM; 30 μM; 
45 μM; 60 μM; 120 μM; 240 μM; 300 μM in the colorimetric analysis 
solutions. Various concentrations of mercury were then added to a final 
concentration of 100 μM. Following gentle shaking, the solution was 
let to stand for twenty minutes. A control spectrum was measured by 
spectrophotometry at 496 nm against a solution without mercury ion. 
300 μL of erythrocyte suspensions were added to the reaction mixture 
and GSNO concentrations were obtained as already described [22]. 
Erythrocyte deformability
The erythrocyte deformability (ED) for different shear stress (0.30, 
0.60, 1.20, 3.00, 12.00, 30.00 and 60.00 Pa) was determined by using 
the Rheodyn SSD shear stress diffractometer from Myrenne GMBH 
(Roentgen, Germany), and erythrocyte deformability is expressed 
as the elongation index (EI) in percentage (20). The Rheodyn SSD 
diffractometer determines RBC deformability by simulating the shear 
forces exerted by the blood flow and vascular walls on the erythrocytes. 
Erythrocytes are suspended in a viscous medium and placed between a 
rotating optical disk and a stationary disk. A well-defined shear force is 
exerted upon the suspension which forces the erythrocytes to deform 
to ellipsoids and align with the fluid shear stresses. If a laser beam is 
allowed to pass through the erythrocyte suspension a diffraction pattern 
appears on the opposite end. That diffraction pattern will be circular 
with resting erythrocytes, but becomes elliptical when the erythrocytes 
are deformed by shear. The light intensity of the diffraction pattern are 
measured at two different points (A and B), equidistant from the center 
of the image. The erythrocyte elongation index (EEI) is expressed as a 
percentage, obtained according the following formula: EEI (%) = [(A – 
B)/ (A + B)] × 100 [23].
This study was performed in accordance with the ethical guidelines 
of Clinical Hemorheology and Microcirculation [24].
Statistical analysis
Data are expressed as mean values ± SD. Student’s paired t-tests 
were used to compare values between different samples of erythrocyte 
suspensions. Statistical analysis was conducted using the Statistical 
Package from the Social Sciences (SPSS; version 16.0). One-way 
analysis of variance and paired t-tests were applied to assess statistical 
significance between samples. Bonferroni post-hoc tests were 
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conducted when appropriate. Statistical significance was set at a 
p<0.05 level.
Results
Using blood samples instead of erythrocytes suspension we mimics 
the experimental model of hyperfibrinogenemia and 510±10mgdL was 
the Fib concentration in the aliquots.
Effects of fibrinogen on erythrocyte deformability under the 
absence an presence of timolol and timolol plus adenylyl and 
guanylyl cyclase inhibitors
No significantly values of erythrocyte deformability at all shear 
stress were observed in all blood aliquots in relation to the control one 
at exception of two of them respectively Fib plus timolol in absence 
(49.2 ± 3.99 vs 47.7 ± 3.11) and presence of MDL (48.9 ± 3.46 vs 47.7 
± 3.11) Table 1. 
Effects of fibrinogen on nitric oxide metabolism e under the 
absence an presence of timolol and timolol plus adenylyl and 
guanylyl cyclase inhibitors
Table 2 shows that the values of NO efflux from erythrocytes, 
obtained in presence of MDL, or timolol or Fib plus Ly do not 
show significant changes in relation to the control blood aliquots. 
Significantly increased values (p<0.02) in relation to control aliquots 
(1.09±0.11) were obtained when Fib is present with MDL (1.50±0.42) 
or with timolol (1.23±0.14) or with MDL plus timolol (1.49±0.36) or 
with Ly plus timolol (1.49±0.36). Comparing the NO efflux values in 
presence of Fib plus MDL plus timolol (1.49±0.36) in relation to the Fib 
aliquot (1.23±0.11) a significantly (p<001) difference was obtained Table 2 
The values of GSNO inside the erythrocytes increase significantly 
(p< 0.02) in all treated blood aliquots in relation to the control aliquots 
Table2. It is highlight, that the value of GSNO of Fib plus MDL plus 
timolol (12.28±0.70) present significantly (p<0.03) increased in relation 
to Fib (9.13±0.34) and to Fib plus MDL blood aliquot (10.86±1.29) 
p<0.05 Table 2. 
In relation to the control group *p<0.02; in relation to the Fib 
groups φ p<0.001 and # p<0.03; in relation to the Fib+MDL group ∆ 
p<0.05 and in relation to Fib+Ly group ◊ p<0.04.
Regarding nitrate values in all treated blood aliquots in relation 
to the control ones they are all significantly (p<0.01) increased Table 
2. When Fib is added to MDL plus timolol the values of nitrate 
(12.28±0.70) were increased significantly (p<0.001) and (p<0.03) also 
in relation to Fib (10.15±0.64) and to Fib plus MDL (11.50±0.84) 
respectively. 
The variation of the nitrites values obtained in treated blood 
aliquots in relation to the control aliquots is almost similar to the 
nitrate with exception of absence changes in the blood aliquots values 
obtained in presence of Fib or MDL Table 2. When Fib is added to 
MDL plus timolol the values of nitrite (12.30±0.59) were increased 
significantly (p<0.001) and (p<0.03) also in relation to Fib (9.45±0.34) 
and to Fib plus MDL (11.10±0.82) respectively.
Discussion 
The present study confirms that erythrocyte deformability is 
not changed by high Fib concentration that in our previously data 
showed increase of ED values when high Fib is under band 3 protein 
dephosphorylated state or in presence of AChE- ACh active complex 
form [8,12]. The ED values are not affected by high Fib levels in absence 
or presence of timolol plus guanylyl cyclase inhibitor Ly in any shear 
stress Table 1. In absence of fibrinogen the AChE-timolol less active 
complex plus MDL blood aliquots did not influence ED values [17].
Erythrocyte deformability increased in blood aliquots with Fib 
plus timolol in absence or presence of adenylyl cyclase inhibitor 
Values of erythrocyte elongations índex in all blood samples aliquots
Shear stress









0.3 1.76 ± 1.29 2.28 ± 1.14 2.05 ± 1.32 1.98 ± 1.00 2.38 ± 1.13 2.96 ± 1.40 2.50 ± 1.23 2.72 ± 1.50 2.75 ± 1.72
0.6 4.79 ± 1.75 5.48 ± 1.87 5.71 ± 1.64 4.94 ± 1.67 6.11±1.32 6.48 ± 1.82 5.72 ± 1.94 5.84 ± 1.52 6.18 ± 2.18
1.2 14.1 ± 2.62 14.6 ± 3.09 15.0 ± 2.73 14.3 ± 2.54 15.2±1.83 15.1 ± 1.84 14.7 ± 2.43 16.1 ± 2.73 15.0 ± 2.39
3 28.9 ± 2.78 29.1 ± 3.14 29.3 ± 2.57 28.7 ± 3.08 30.0±1.97 29.6 ± 1.70 29.0 ± 2.52 30.2 ± 2.44 29.2 ± 2.25
6 38.6 ± 2.24 37.4 ± 2.76 38.7 ± 2.08 37.9 ± 2.27 39.2±1.81 38.2 ± 2.10 38.6 ± 2.27 29.3 ± 2.28 38.6 ± 2.51
12 44.7 ± 2.62 44.9 ± 2.06 44.8 ± 2.00 44.7 ± 2.04 45.6±2.29 44.8 ± 3.79 45.3 ± 2.44 45.7 ± 2.31 45.2 ± 3.69
30 47.7 ± 2.94 48.2 ± 2.96 47.7 ± 3.06 48.2 ± 2.73 48.7±2.75 48.3 ± 5.50 48.9 ± 3.63 48.6 ± 2.98 48.7 ± 5.17
60 47.7 ± 3.11 49.0 ± 3.84 48.0 ± 3.40 48.5  3.00 48.8±3.17 48.5 ± 6.03 49.2 ± 3.99* 48.9 ± 3.46* 48.9 ± 5.8
Table 1. Values (Mean±SD) of erythrocyte elongation index at different shear stress obtained in absence (Control) and presence of fibrinogen (Fib) or Fib plus timolol or Fib plus adenylyl 
cyclase inhibitor (MDL), or plus guanylyl cyclase inhibitor(Ly).
*p<0.03 in relation to control aliquot 
Blood samples Nitric oxide GSNO Nitrate Nitrite
Control 1.09±0.11 8.05±0.62 9.30±0.82 8.60±1.33
Fib 1.23±0.11* 9.13±0.34* 10.15±0.64* 9.45±0.34
MDL 1,17±0.22 9.12±1.18* 10.15±0.76* 9.25±0.78
Timolol 1.20±0.17 10.09±0.85* 10.95±0.63* 10.45±0.67*
Fib+MDL 1.50±0.42* 10.86±1.29* 11.50±0.84* 11.10±0.82*
Fib+Ly 1.23±0.18 11.16±1.43* 11.55±0.69* 10.93±0.87*
Fib+Timolol 1.23±0.14* 11.84±0.57* 12.00±0.39* 11.60±0.67*
Fib+MDL+Timolol 1.49±0.36*φ 12.28±0.70*φ∆ 12.20±0.46*∆ 12.30±0.59*φ∆
Fib+Ly+Timolol 1.28±0.15* 11.36±1.23*φ 12.10±0.67*◊ 11.60±0.67*φ◊
Table 2. Values (Mean±SD) of erythrocyte nitric oxide efflux (nM), GSNO (µM), nitrite (µM) and Nitrate (µM) obtained in absence (Control) and presence of fibrinogen (Fib) or Fib plus 
timolol or Fib plus adenylyl cyclase inhibitor (MDL),or plus guanylyl cyclase inhibitor (Ly).
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MDL, at high shear stress, Table 1. So, cAMP synthesis, are affected 
by the presence of AChE- timolol les active form and by Fib-CD47 
receptor complex because both type of complexes are associated to 
Gi protein and consequently adenylyl cyclase inhibition [4, 9,10]. Our 
results evidenced the effect of Fib in ED is synergic with timolol plus 
or not with MDL because maintaining cAMP synthesis inhibited. In 
erythrocytes MDL activate PKC which phosphorylated PDE-3 left it 
in inactive state without cAMP hydrolysis 25. The activation of PKC 
increased ED as showed [26]. PKC phosphorylates PTK and protein 
tyrosine phosphatase (PTP) proteins promoting activation and 
inhibition of their enzyme activities respectively resulting in band 3 
phosphorylation [27]. So, in erythrocytes MDL has double function to 
inhibit the adenylyl cyclase enzyme and be an indirect factor of band 3 
protein phosphorylation.
We verify in this study the synergic effect of Fib and timolol in 
terms of cAMP synthesis inhibition to be a contributing factor for the 
increase RBC ability to deform at high shear stress, Table 1. 
The ability of erythrocyte to modify reversibly the discoid shape, 
allowing in vivo, its passage through the capillary network, depends 
on its own erythrocyte membrane cytoskeleton, internal viscosity and 
the area per volume ratio [28]. The integrin associate protein CD 47 is 
near Rh complex and establish interaction with 4.2 protein which in 
turn is associated with and ankyrin [29]. The erythrocyte cytoskeleton 
protein spectrin is associated with the integral band 3 protein by the 
ankyrin protein [30]. It was previously described by us that when the 
protein band 3 phosphorylation degree was modulated with inhibitors 
of PTK syk and PTK p53/56Lyn and of PTP, the erythrocyte elongation 
index (EEI) as a measure of deformability, was not affected [31]. At 
variance when band 3 protein is dephosphorylated by the presence 
of syk inhibitor plus high Fib concentrations and at low shear stress 
ED values are elevated [32]. The results showed in this study, Table 1, 
evidenced that the assemble of Fib and timolol (binding respectively 
to CD47 and AChE both associated to Gi protein inhibitor of adenylyl 
cyclase) increased ED by the sustained lower levels of cAMP. 
The NO efflux from erythrocyte determined in vitro model of 
hyperfibrinogenemia they did not present statistical significance 
differences in relation to control blood aliquots [6,8,17,32]. Regarding 
the effects of Fib in NO efflux from erythrocytes, in the present study, 
we verified increased values in relation to control aliquots Table 2. We 
based our explanation in the fact that band 3 protein is a transmembrane 
protein which co-exist in a dynamic balanced between phosphorylated 
and dephosphorylate degree states [33] .We have verified that when 
band 3 protein is phosphorylated or dephosphorylated in others 
studies using equal in vitro model of hyperfibrinogenemia that the 
values of NO efflux increased without a constant profile [6,32]. This 
means that Fib plus band 3 phosphorylated could induced higher or 
lower NO efflux values than the band 3 dephosphorylate [6,32]. The 
heterogeneity of blood samples is real and known in dependence also of 
the degree of hemoglobin oxygenation. Band 3 when dephosphorylated 
binding oxygenated hemoglobin and glycolytic enzymes [29,34]. On the 
other hand Fib binding CD47 may induce changes in the band 3 protein 
structure interaction with other cytoskeleton membrane protein and 
consequently phosphorylation degree modifications as mentioned above. 
The present study confirms that timolol do not changes the NO 
efflux values in relation to those obtained with control values [13-17]. 
When MDL and timolol are both present in blood aliquots the NO 
efflux from erythrocyte increase in relation to control aliquots [17]. 
The present study showed that Fib affects positively the NO efflux 
from erythrocytes in presence of MDL without or with timolol Table 
2. These results confirm previous that the high NO efflux amount from 
erythrocytes under high Fib levels depends on low levels of cAMP [7]. 
Fib did not affect the values of NO efflux verified on presence of timolol 
without or with guanylyl cyclase inhibitor Ly Table 2. Besides, both 
MDL and Ly increase the activity of PKC with consequently increased 
of cAMP, in turn MDL inhibits its synthesis [25] favoring the Fib-
CD47 complex dependence of low cAMP concentration to mediate the 
efflux of NO from erythrocytes Table 2.
For the first time we have showed lower GSNO efflux from 
erythrocytes with AChE- timolol less active form than with the 
AChE-ACh complex active form [15]. Consequently, the amount 
of GSNO efflux has influence on GSNO concentration presented 
inside erythrocytes as evidenced in RBCs of glaucoma patients when 
compared with healthy donors [16]. When timolol is added to MDL or 
to Ly in blood aliquots the GSNO increase in relation to control aliquots 
[17]. In the present study timolol increase GSNO in relation to control 
and the positive synergic action of Fib on the GSNO values obtained in 
presence of timolol plus MDL in relation to control, to Fib plus MDL 
and to Fib plus timolol was showed in Table 2. The increase levels of 
GSNO result from the NO captured by reduced glutathione (GSH) 
which may be available from the improvement of pentose phosphate 
pathway at expense of glycolysis inhibition by the pyruvate kinase 
(PK) phosphorylation [35]. As described above PK is phosphorylated 
by cAMP protein kinase (cAMPK) dependent which activation results 
from the activation of PKC by MDL or by Ly [25]. 
The positive synergic effect pays by Fib when added to timolol 
plus MDL or Timolol plus Ly is showed in both nitrite and nitrate 
concentration Table 2. It is known that the binding of Fib to CD47 in 
erythrocytes do not induce an oxidant state in erythrocyte, as indicate 
by the normal peroxynitrite values evaluated [7]. Also no variation of 
erythrocytes peroxynitrite concentration was obtained with timolol 
in absence or plus MDL or plus Ly [17]. So, it is not to exclude the 
possible reaction of peroxynitrite with hemoglobin generates nitrate 
and S-nitrosohemoglobin, which liberating NO to thiol group of GSH 
originates GSNO [36]. The increase in nitrite and nitrate concentration 
obtained in the present study can be derived from the peroxynitrite 
decomposition [37]. These two hypothesis need to be confirmed in 
further study.
Conclusions
Fibrinogen increased erythrocyte deformability under timolol 
without or with adenylyl cyclase inhibitor MDL, at high shear stress in 
dependence of lower cAMP levels.
Fibrinogen plus timolol do not interfere in the effect of NO efflux 
from erythrocytes neither in the values of GSNO, nitrite and nitrates 
but in opposite those values are increase under the influence of adenylyl 
cyclase inhibitor, MDL.
Like for all biological parameters, it is necessary to highlight, in a 
simplistic way, that for each molecule component of the NO metabolism 
independent of the internal or external addition molecules, there are a 
range of initial values or control ones in dependence of the biological 
sample variability. From this derive the importance of our “in vitro” 
experimental model. 
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